Brief: Aptose Announces Updated Clinical Responses, Breadth Of Activity, And Safety Across Four Dose Levels Of Tuspetinib In Difficult-To-Treat Acute Myeloid Leukemia Populations
11/12/2022 14:05
Dec 11 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE ANNOUNCES UPDATED CLINICAL RESPONSES, BREADTH OF
ACTIVITY, AND SAFETY ACROSS FOUR DOSE LEVELS OF TUSPETINIB IN
DIFFICULT-TO-TREAT ACUTE MYELOID LEUKEMIA POPULATIONS
* APTOSE - TUSPETINIB SAFETY & EFFICACY PROFILE MAY POSITION
DRUG
TO BECOME PREFERRED KINASE INHIBITOR FOR TRIPLET COMBINATION,
MAINTENANCE THERAPY
* TUSPETINIB ENROLLING APTIVATE EXPANSION TRIAL FOR
MONOTHERAPY
AND COMBINATION THERAPY
Source text for Eikon: ID:nGNXbzZc6k
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting